Pidilizumab

Monoclonal antibody

none

IdentifiersCAS Number

1036730-42-3^Y

ChemSpider

none

UNII

B932PAQ1BQ

KEGG

D10390

Chemical and physical dataFormulaC₆₄₂₄H₉₉₂₀N₁₇₀₄O₂₀₀₂S₄₈Molar mass144594.83 g·mol⁻¹

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.^[1]^[2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.^[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

Clinical trials

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.^[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.^{[citation needed]} An add-on trial for multiple myeloma is ongoing.^[5]

References

^ Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. (January 2014). "Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial". The Lancet. Oncology. 15 (1): 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
^ Carroll J (26 January 2016). "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study". Fierce Biotech.
^ "Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data". Genetic Engineering & Biotechnology News. September 2011.
^ Clinical trial number NCT02077959 for "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma" at ClinicalTrials.gov

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab